Given the immunotherapy resistance observed in patients with KRAS-mutated NSCLC and the ongoing clinical trials of KRASG12C inhibitors combined with immunotherapy, the pharmaceutical effect of a combination therapy with tricin and an anti-PD-1 inhibitor was explored in a mouse LLC cell xenograft model. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.